1 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 A PATIENT-FRIENDLY BREAST CANCER BLOOD TEST AGM Presentation – November 2021 BCAL Diagnostics Limited (ASX:BDX) 2 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 IMPORTANT NOTICE & DISCLAIMER This presentation ( Presentation) has been prepared by BCAL Diagnostics Ltd ABN 51 142 051 223 ( BCAL or the Company ). The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this Presentation is subject to change without notice and, subject only to any legal obligation to do so, BCAL does not have any obligation to correct or update the contents of this Presentation. The Presentation contains certain “forward-looking statements”. The words “forecast”, "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice and involve known and unknown risks and certainties and other factors which are beyond the control of BCAL, and its directors and management, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. This includes statements about market and industry trends, which are based on interpretations of current market conditions. In particular, the market data was prepared before the onset of COVID-19, the final economic effect of which is currently not possible to predict with any certainty. Consequently, while the Company has no reason to believe that the markets to which the data relates will not return to the operating levels experienced before COVID-19, the impact of COVID-19 (if any) on the market data that is referenced is not possible to currently predict with any certainty and investors are cautioned against placing undue reliance on such data. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumption on which these statements are based. Recipients are cautioned not to place undue reliance on forward-looking statements. Refer to the risk factors section of this Presentation and in the Pathfinder for some of the key know risks. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward looking statements are based on information available to BCAL as at the date of this Presentation. Circumstances may change and the contents of this Presentation may become out-dated as a result. Except as required by law or regulation, none of BCAL, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward looking statements. No party other than BCAL has authorised or caused the issue, lodgement, submission, dispatch or provision at the end of this Presentation, or takes any responsibility for, or makes or purports to make any statements, representations or undertakings in this Presentation. To the maximum extent permitted by law, BCAL (including its subsidiaries, related bodies corporate, shareholders, affiliates, advisers and agents): • disclaims all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation; • disclaims any obligations or undertaking to release any updates or revision to the information in this Presentation to reflect any change in expectations or assumptions; and • does not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the information in this Presentation or the likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement. 3 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 BCAL SNAPSHOT BCAL is commercialising a blood test for breast cancer diagnosis There are currently NO routine early detection and monitoring testing options for breast cancer globally 4 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 INVESTMENT HIGHLIGHTS Experienced Board, team & SAB with extensive expertise in breast cancer Blood test for range of breast cancers where none currently exists Cheaper and easier to administer compared to mammography, the current gold standard Widens population for screening including under 40s and those in rural areas Clear rollout strategy with staged clinical pathway in Australia, US and EU Accurate identification of cancer in early stages, independent of age A more effective, patient-friendly breast cancer test 5 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 BREAST CANCER IS A LEADING CAUSE OF DEATH US Australia Global Annual new cases Annual deaths 281,550 43,600 Annual new cases Annual deaths 20,000 3,000 Annual new cases Annual deaths 2,000,000 627,000 Initial market Follow-on market Initial market Follow-on market Estimated 1-in-7 women at risk of a breast cancer diagnosis 50% of breast cancer cases and 58% of deaths come from developing economies 6 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 EARLY DIAGNOSIS IS CRITICAL Early breast cancer diagnosis leads to better survivability Stages of breast cancer Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 Breast cancer survivability 100% survival rate 98% survival rate 93% survival rate 72% survival rate 28% survival rate 7 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 DIAGNOSIS A BOTTLENECK TO SURVIVABILITY Self-examination Mammogram Biopsy Surgery Discovery Screening Testing Treatment 80% are benign (false positives) 20% require treatment Chemo- therapy Radiation therapy 10% go to biopsy Opportunity for blood test Improve the accuracy of breast cancer detection Early breast cancer diagnosis leads to better survivability 3.8m women p.a undergo unnecessary biopsies ~47m mammograms p.a. completed in US, EU and Australia Approximately 50% of women self-exclude from mammograms Suitable for the ~94m p.a. in target markets Also, 8m false negatives, leading to delay of critical treatment 8 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 NO EARLY DETECTION TESTS FOR BREAST CANCER $3.6B $6.2B $1.4B $2.5B 2019 2027 Imaging Other US$5.0B US$8.7B CAGR: 7.3% IVD blood & plasma tests No blood test for breast cancer Mammogram MRI Ultrasound Gold standard. Typically US$150-200 per screen US$300+ per screen but requires expertise for operation and interpretation Used to support a diagnosis with a mammogram Human Epidermal Growth Factor Receptor 2 (HER2) has proved useful but only relevant for a quarter of breast cancers There are currently NO routine early detection and monitoring testing options for breast cancer 39m mammograms p.a. completed in US alone 9 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 KEY DEVELOPMENT / SCIENTIFIC MILESTONES Founded as SBC Research (born from Sydney Breast Clinic) to commercialise a novel and universal breast cancer-screening test 2010-2013 Completed in vitro studies that identified alterations in certain lipids from breast cancer cells 2013-2017 “Proof of concept” studies with North American and Australian partners to confirm that the lipids of interest were detected in cell signals 2018-2021 Completed studies whose results showed accurate identification of cancer especially in early stages, independent of age, with 91% sensitivity and 87% accuracy from 18 lipid markers Established research operations at the Charles Perkins Centre - at the University of Sydney 2010 Changed name to BCAL Diagnostics Ethical approval granted for Stage 1 clinical trial at Sydney hospitals and breast cancer clinics 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 In vitro studies Proof of concept studies Cohort testing (cohorts 1 to 4) Significant development to date to bring BCAL to current position 10 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 ROLLOUT STRATEGY 1. Adjunct test to traditional mammogram screening 2. Monitor breast cancer patients through the disease lifecycle 3. Monitor women who carry the BRCA1 and BRCA2 gene 4. Comprehensive breast cancer screening for all patients Adjunct test Monitoring Predictive Screening Strategy defined to provide a sequenced path to market No safe routine early detection diagnostic currently in the market with women opting for breast removal Improves mammography results to better accuracy Clinical studies will provide data to support each of these claims No monitoring diagnostic currently in the market for women who have had breast cancer Improvements of AI algorithm positions as a diagnostic long term 11 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 BIOMARKERS OPEN DOOR FOR BLOOD TEST Altered lipid expression can be detected using a relatively simple process Cell signal Cell signal Plasma (55% of total blood) Red blood cells (45%) White blood cells & platelets (<1%) Cell Blood-Plasma Breast-cancer altered lipids in plasma can be detected in a blood test using BCAL’s lipid biomarker algorithm 18 lipid candidate markers that reveal differences between breast cancer and non- breast cancer patients 12 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 HOW IT WORKS Blood collected at standard blood collection point Extracellular vesicles (EV) enrichment from blood plasma Data analysis of markers (AI & ML algorithm to drive higher accuracy and sensitivity) Evaluation by Liquid Chromatography Mass Spectrometry (LCMS) Extraction of markers for evaluation BCAL Blood Test Patient-friendly test, easy to collect as any blood test 13 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 Cohort 1 N=90 Cohort 4 N=301 Cohort 3 N=201 Cohort 2 N=200 Control IDC DCIS ILC STUDIES 2018 TO DATE Proof of concept studies US 2013- 2017 2018-2021 Results Commencing BCAL Trial 1 2022 Trial to determine Feasibility of BCAL as adjunct test to mammogram and establish workflow • Cohort refers to a group of people who share a certain characteristic, in this case presence of absence of breast cancer at ~ 50:50 ratio for cohorts 1-3 • A marker is a specific lipid whose level is helpful in distinguishing between breast cancer and healthy samples 14 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 ALGORITHM DEVELOPMENT AND BIOMARKERS Small and medium biomarker panels were selected based on the ability to discriminate between cancer and control across several cohort subsets 18 # Panels of lipids combine the discriminating power of individual lipids to deliver a likelihood of cancer for a new sample. Algorithms are trained on the BCAL cohorts of cancer patients and matched controls. The focus is on detection of early-stage cancer. New Patent applications proceeding ~450 LIPIDS 15 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 0 10 20 30 40 50 60 70 80 90 100 Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 3&4 Reproducible performance for Early detection Accuracy Sensitivity Specificity ALGORITHM PERFORMANCE 2018-2021 • Early cancer could be detected from lipid profiles • Detection capability improves with increased sample sets for tuning • Small panels are advantageous and can provide robust performance Findings • Identified a panel of 18 candidate lipid markers • Robustly and reproducibly discriminate between control and breast cancer in early stages 16 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 CLINICAL STUDY PROGRAM Study 1, Stage 1 Study 1, Stage 2 Study 2 Collection type Single Single Multiple Aim Feasibility of BCAL as adjunct test to mammogram and establish workflow Test as adjunct test to mammogram Monitoring tool for recurrence Target findings • Initial performance of 18 candidate markers • Optimise algorithm • Establish workflow • Assess performance of algorithm from Stage 1 • Compare results to mammogram • Evaluate 18 markers before and after surgery • Evaluate before and after post- treatment to track recurrence • Identify better markers for disease monitoring Clinical partners • Lead breast care surgeons and clinicians at NSW BreastScreen in Sydney Local Health District at the Royal Prince Alfred Hospital • Chris O’Brien Lifehouse • Sydney Breast Clinic (SBC) • NSW Health Statewide Biobank • Genesis Care No of Participants 1,000 2,000 2,500 Results to support claim as adjunct test to traditional mammogram screening Results to support claim to monitor breast cancer patients through the disease lifecycle 17 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 NEAR TERM TARGETS H2 2021 H1 2022 H2 2022 H1 2023 H2 2023 Finalise biomarkers Sign NATA accredited lab Prepare for in-house IVD Analytical performance Cohort 5 (1,000 samples) Pivotal Clinical Trial Provide data for the technical file for regulatory submission 18 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 ACHIEVEMENTS FY21 • Established & built out a strong scientific team. • Completed analysis of cohort 4 n=301, reinforcing strong data. • Updated patent claims in the USA, Canada and Europe using new findings. • Establishing a quality system in preparation for ISO certification. • Executed commercial agreements with Izon and CORE Dx. • Initiated three key clinical study sites in Sydney with another expected. • Commenced recruitment for clinical trial. 19 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 KEY PARTNERS University of Louisville (USA) Strong group of university and commercial partners to accelerate commercialisation IP owners provides rights to BCAL to 2031 Patents granted in Australia, EU and Japan. Patents pending in USA, Canada + additional in EU The Sydney Breast Clinic (Australia) Intellectual property Research and Development Clinical studies Downstream partners Izon (New Zealand) Royal Prince Alfred Hospital (Chris O’Brien Lifehouse) (Australia) IVD kit research Market entry partner in Australia, UK, Spain and USA Genesis Care (Australia) Thermo Scientific (Australia & USA) IVD kit production Genesis Care (Australia) Insight Stats 20 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 KEY PARTNERSHIP – GENESIS CARE Master Services Agreement signed with GenesisCare as Contract research organisation (CRO) and market entry partner Currently participating in over 120 investigator-led and sponsored clinical trials Clinical network of more than 6,000 doctors, specialists and support staff reaching over 440,000 patients globally CRO and Market entry partner in Australia, UK, Spain and the USA US 300 centres Spain 21 centres UK 14 centres Australia 36 centres Over 440 centres globally including in key territories 21 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 COMMERCIAL PATHWAY 2021 2022 2023 2024 2025+ Regulatory LDT Launch Product 1.0 Adjunct to mammogram Develop Product 3.0 monitoring Complete studies 1 and 2 to provide documentation for regulatory submissions in Australia, EU and US Establish and expand sales channels using cleared claims Progress monitoring and early warning products to market Develop Laboratory Developed Test (LDT) via CLIA certified “High Complexity” Laboratory USA to create initial access and acceptance Regulatory submissions to Australia, EU and US markets Clinical Study 1 Stage 1 Clinical Study 1 Stage 2 and Study 2 Develop Product 2.0 Adjunct improved Launch 22 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 4. KEY PEOPLE 23 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 BOARD OF DIRECTORS Jayne Shaw Executive Chair The Hon Ron Phillips AO Non-executive Director Jonathan Trollip Independent Non-executive Director Dr. Merilyn Sleigh Independent Non-executive Director Mark Burrows AO Independent Non-executive director • Co-owner of Sydney Breast Clinic and a co-founder of BCAL Diagnostics with Ron Phillips • Experienced healthcare Board member including Cardiology, Orthopaedics, and Women’s Health • Previously established an Australian and international consulting business which was sold to Healthsouth a large USA Healthcare company, and was co-founder of Vision Group, that was successfully listed on the ASX • Continues to work with private equity firms on local and international healthcare transactions • Current Board positions are The Woolcock Research Institute, The Citadel Group, Corum Group (ASX: COO) and Mabel Technologies • Co-owner of Sydney Breast Clinic which was recently sold to Healthscope and a co-founder of BCAL Diagnostics • Previously developed a successful consulting business in the Health and Aged Care Industry • Recently retired as Chair of the Sydney Local Health District and as Director of Westmead IVF • Served 15 years in the NSW Parliament which included serving as Minister for Health and Deputy Leader of the Opposition • A globally experienced Director with over 30 years of commercial, corporate, governance and legal and transactional expertise • Currently non-executive Chairman of ASX listed Global Value Fund Ltd Future Generation Investment Company Ltd , Antipodes Global Investment Company Ltd and Plato Income Maximizer Limited • He is a non-executive director of ASX listed Kore Potash Limited and holds private company directorships in the commercial and not-for-profit sectors • Previously a partner with law firm Herbert Smith Freehills • A Fellow of the Australian Institute of Company Directors • Over 30 years’ experience as a senior executive and non-executive director in Australia’s biotechnology sector • Previously Chief Executive Officer and Managing Director of EvoGenix Limited, that listed on the ASX before acquisition by a larger company • Held non-executive director positions with ASX-listed companies Clover Corporation, Tyrian Diagnostics Ltd and Adalta Ltd • Formerly Dean of the Faculty of Life Sciences, University of NSW; Director of Research & Development at Australian biotech Peptech Ltd and a research scientist and senior manager with CSIRO • Holds a Doctorate in Philosophy and is a Fellow of the Australian Institute of Company Directors • An advocate for early diagnosis of breast cancer and other cancers • Cofounded Baring Brothers Burrows & Co in Australia in the early 80s, then in 1999 was appointed the Managing Director / Deputy Chairman of ING Barings in London. Joined Lazard as a Managing Partner and was appointed Lazard Australia’s inaugural Chairman • Has been a principal financial advisor to some of the most significant and transformative corporate and government transactions in Australia • Served as a Non-Executive Director for Australian and UK public companies including as Chairman and Deputy Chair of Brambles, Fairfax Media and Telstra • Advised the United Nations, G20 and corporates on climate initiatives relating to the financial sector 24 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 KEY PEOPLE Dr. Jane Ryan , PhD Chief Operating Officer Guy Robertson Chief Financial Officer & Company Secretary Dr. Amani Batarseh Chief Scientist Alison Cook (Mew) , MSc Regulatory and Commercialisation Manager • Over 30 years of international pharmaceutical and biotechnology experience • Worked in Australia, the USA and UK with companies including Peptech, Roche, Cambridge Antibody Technology and Biota Holdings • Led many successful fundraising campaigns and licensing initiatives including the awarding of a $230m USA Government contract • Chairs the Advisory Board of the i3 Institute at the University of Technology Sydney (UTS) • A Non-executive Director at ASX listed, Anatara Lifesciences • Previously a Board Member of the Victorian Endowment for Science Knowledge and Innovation (veski), Diabetes Victoria, TechInSA, and the Diabetes Vaccine Development Centre • A Finance Director/Chief Financial Officer for a number of companies within the Jardine Matheson Group over a period of 16 years • Provided CFO consulting services to many large corporations and SMEs • CFO/Company Secretary for a number of Australian public companies including Evogenix Limited and is currently a Director of ASX-listed entities Metal Bank Limited and Hastings Technology Metals Ltd • Company Secretary for Bioxyne Limited, Artemis Resources Limited and Truscreen Limited • Graduated magna cum laude from La Roche College in Pennsylvania where she had a Pacem in Terris scholarship for academic excellence • Received a fellowship to pursue her PhD at Georgetown University, Washington, DC in Biochemistry and Molecular & Cellular Biology • Completed post-doctoral studies at Harvard University, McGill University and Wollongong University • In Canada managed and established two mass spectrometry laboratories at the Research Institute of McGill University Hospital and The Glen Hospital in Montreal, respectively • Expertise combines molecular biology with lipidomics and mass spectrometry to answer biological questions • Management and leadership experience of more than 30 years across the biopharmaceutical, diagnostic and health service sectors • Previously CEO of Genetic Technologies Ltd, and spent 13 years in senior executive roles at CSL Limited • At CSL Limited, served in senior executive positions across the Animal Health, Biosciences and Pharmaceutical Divisions • Consulted widely across the life sciences industry, including in technical operations, strategy and management, and is familiar with healthcare’s complex technical and regulatory requirements • Holds a Master of Science (Microbiology) and graduated from the Executive Development Program at Melbourne Business School 25 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 SCIENTIFIC ADVISORY BOARD Dr Kim Ekroos PhD, Lipidomics Consulting A/Prof Craig Gedye BSc(Hons), MBChB, FRACP, PhD Prof Peter Meikle PhD, Baker IDI Lipidomics Melbourne • Founder and CEO of Lipidomics Consulting Ltd., a consulting business providing unique services for customers globally in the field of Lipidomics with over 20 years academics, healthcare and industry expertise • Received his Ph.D. in biology from the Technical University in Dresden, Germany. His expertise includes high-throughput technologies for the precise assessment of lipidomes enabled by advanced mass spectrometry, automation, and software tools towards discovery of biological architectures and of diagnostic biomarkers for clinical purpose • Has a number of patents for biomarker discovery, numerous peer- reviewed publications and an editor of a widely read Lipidomics book. • Current president of the newly founded International Lipidomics Society. • A medical oncologist and cancer researcher working for people with melanoma, brain, prostate, bladder and kidney cancers at the Calvary Mater Newcastle, and is the Clinical Research Director at the NSW Health Statewide Biobank • His research in the School of Medicine and Public Health at the University of Newcastle/Hunter Medical Research Institute focuses on complexity and heterogeneity in cancer. • Leads several national cancer clinical trials for the ANZUP and COGNO trials groups, and is a member of the Mark Hughes Scientific Advisory Committee, HNEHLD Clinical Trials Ethics Subcommittee and ANZUP Cancer. • Has been awarded numerous scholarships, fellowships, grants, investigator-initiated clinical trials, publications, conference presentations and prizes. • Peter is an NHMRC Senior Research Fellow at the Baker Institute. • He leads the Obesity and Diabetes Program and is Head of the Metabolomics laboratory. • He is also Editor in Chief of the journal Metabolites and holds affiliate positions at the University of Melbourne, Monash University and the NHMRC Clinical Trials Centre, University of Sydney. • The Metabolomics laboratory uses state of the art tandem mass spectrometry to obtain metabolic profiles from cell and animal models in addition to clinically relevant human samples. This approach is providing an improved understanding of disease mechanisms leading to new biomarkers for improved diagnosis and risk assessment as well as new therapeutic strategies in the areas of obesity, diabetes and cardiovascular disease. 26 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 CLINICAL ADVISORY BOARD A/Prof Sanjay Warrier (Associate Prof.) BSc (Med) MBBS FRACS MS A/Prof Cindy Mak MBBS (Hons) Sydney University FRACS Prof Mary Rickard OAM MBBS, BSc(Med)(HonsII), DRACR, DDU, MPH, RANZCR • Consultant Breast Oncology and Oncoplastic Surgeon at Chris O’Brien Lifehouse, Royal Prince Alfred and Mater Hospitals. He is also a Visiting Medical Officer at BreastScreen NSW. • An Associate Professor of the University of Sydney with the Royal Prince Alfred Academic Institute. He is lead researcher at the Institute with goals of developing and creating a culture of academia within the Breast Department. • Won the Patron’s Prize at the Royal Prince Alfred Hospital for best scientific research. Sanjay has also published many papers and co- authored articles in peer reviewed journals and magazines. • Sanjay is Chairman of Post-Fellowship Training for BreastSurgANZ, a role that involves training future breast surgeons in Australia and New Zealand. • Completed her medical training with Honours at Sydney University. • Appointed the Breast Fellow and Surgical Superintendent at Concord Hospital and fellow and consultant surgeon at Edinburgh Breast Unit, one of the largest breast units in the UK • Currently Director of Breast Services at Chris O’Brien Lifehouse (Camperdown) and also operates at the Mater Hospital (North Sydney) and Royal Prince Alfred Hospital. • A Visiting Medical Officer at BreastScreen NSW, a member of the Australasian Society for Breast Disease, the ANZ Breast Cancer Trials Group, the Australian Medical Association and is an honorary scientific officer at The Garvan Institute. • An active member of Breast SurgANZ, the speciality society for surgeons treating breast cancer. • Received a Member of the Order of Australia award in 2002, for service to medicine through the integration of population-based screening for early detection of breast cancer, and the development of education programs for health professionals. • Involved in consulting with numerous breast screening and diagnostic training programs across South East Asia, in particular Singapore, Indonesia, Malaysia, Thailand, Japan and most recently Mongolia. 27 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 IN SUMMARY Experienced Board, team & SAB with extensive expertise in breast cancer Blood test for range of breast cancers where none currently exist Cheaper and easier to administer compared to mammography, the current gold standard Widens population for screening including under 40s and those in rural areas Clear rollout strategy with staged clinical pathway in Australia, US and EU Accurate identification of cancer in early stages, independent of age A more effective, patient-friendly breast cancer test 28 BCAL DIAGNOSTICS LIMITED AGM PRESENTATION – NOVEMBER 2021 ,,, ,,,
More from BCAL Diagnostics Limited
Join Listcorp to create a personalised news feed, follow your favourite companies, save useful news, and more.